Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Suspended × Carcinoma, Non-Small-Cell Lung × alirocumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 1

Interventions

Specimen Handling 2 pembrolizumab 1 osimertinib 1 icotinib 1 famitinib 1 durvalumab 1 dabrafenib 1 ceralasertib 1 cemiplimab 1 alirocumab 1 Surgical Procedures, Operative 1 Radiotherapy 1 Radiation 1 Pemetrexed 1 Panitumumab 1 Nivolumab 1 Monatide (IMS 3015) 1 Magnetic Resonance Spectroscopy 1 Ipilimumab 1 Immunoglobulin G 1 Immune Checkpoint Inhibitors 1 Gefitinib 1 Eflornithine 1 Drug Therapy 1 Disulfides 1 Cisplatin 1 Celecoxib 1 CTLA-4 Antigen 1 Biopsy 1 Biological Assay 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06385262 2026-03-06

TOP 2301: Neoadjuvant Chemo for NSCLC

Duke University

Phase 2 Suspended

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡